Human pregnane X receptor: Genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity

Journal of Clinical Pharmacology

Volumn 46, Issue 11, 2006, Pages 1356-1369

  He, Ping ^a   Court, Michael H ^b   Greenblatt, David J ^a,b   Von Moltke, Lisa L ^a  

^a Division of Clinical Pharmacology   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A metabolic activity; hPXR; SNP; Splice variant

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ARGININE; CYTOCHROME P450 3A; GLYCINE; MESSENGER RNA; MIDAZOLAM; PREGNANE X RECEPTOR; PROLINE; SERINE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; EUROPEAN AMERICAN; EXON; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HISPANIC; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; RECEPTOR GENE; RNA SPLICING;

ADULT; AFRICAN AMERICANS; ALTERNATIVE SPLICING; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIVER; MALE; MIDAZOLAM; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; RECEPTORS, STEROID; RNA, MESSENGER;

EID: 33749864288     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006292125     Document Type: Article

References (35)

1. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica. 2002;32:165-206.
2. Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab. 2004;5:483-505.
3. Hesse LM, Sakai Y, Vishnuvardhan D, Li AP, von Moltke LL, Greenblatt DJ. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol. 2003;55:1229-1239.
4. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819-850.
5. Fukuen S, Fukuda T, Matsuda H, et al. Identification of the novel splice variants for the hPXR in human livers. Biochem Biophys Res Commun. 2002;298:433-438.
6. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;11:555-572.
7. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102:1016-1023.
8. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol. 2000;14:27-39.
9. Barwick JL, Quattrochi LC, Mills AS, Potenza C, Tukey RH, Guzelian PS. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol. 1996;50:10-16.
10. Xie W, Barwick JL, Simon CM, et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 2000;14:3014-3023.
11. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol. 1999;56:1329-1339.
12. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol. 2002;62:359-365.
13. Burk O, Koch I, Raucy J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279:38379-38385.
14. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998;92:73-82.
15. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
16. Blumberg B, Sabbagh W Jr, Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998;15:3195-3205.
17. Moore LB, Maglich JM, McKee DD, et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol. 2002;16:977-986.
18. Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos. 2001;29:1454-1459.
19. Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos. 2004;32:149-154.
20. Koyano S, Kurose K, Ozawa S, et al. Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab Pharmacokinet. 2002;17:561-565.
21. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab. 2005;6:369-383.
22. Lim YP, Liu CH, Shyu LJ, Huang JD. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet Genomics. 2005;15:337-341.
23. Lamba V, Yasuda K, Lamba JK, et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol. 2004;199:251-265.
24. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998;95:12208-12213.
25. Gardner-Stephen D, Heydel JM, Goyal A, et al. Human PXR variants and their differential effects on the regulation of human UDP- glucuronosyltransferase gene expression. Drug Metab Dispos. 2004;32:340-347.
26. Dotzlaw H, Leygue E, Watson P, Murphy LC. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res. 1999;5:2103-2107.
27. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse and rat liver microsomes. Pharmacology. 1993;47:268-276.
28. Court MH, von Moltke LL, Shader RI, Greenblatt DJ. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos. 1997;18:213-226.
29. Patki KC, von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochrome P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos. 2003;31:938-944.
30. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther. 2003;74:121-129.
31. He P, Court MH, Greenblatt DJ, von Moltke LL. Genotype-phenotype associations of CYP3A4 and CYP3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther. 2005;77:373-387.
32. Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol. 2000;410(2-3):107-120.
33. Cotreau MM, von Moltke LL, Beinfeld MC, Greenblatt DJ. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. J Pharmacol Toxicol Methods. 2000;43:41-54.
34. Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos. 2006;34:131-137.
35. He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos. 2006;34:1198-1207.